Literature DB >> 20856725

When is standard treatment sufficiently active to make use of a placebo-controlled trial unethical?

Hans W Grünwald, Courtney D Storm, Geraldine M Jacobson.   

Abstract

Research has demonstrated that double blinding can lessen the potential for bias in study outcomes, such as perceiving a drug as more effective in the experimental arm of a study. Effective double-blinding techniques minimize the influence of investigator and patient expectations.

Entities:  

Year:  2009        PMID: 20856725      PMCID: PMC2790645          DOI: 10.1200/JOP.0922503

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  3 in total

1.  Does a drug do better when it is new?

Authors:  R Fossati; C Confalonieri; G Apolone; S Cavuto; S Garattini
Journal:  Ann Oncol       Date:  2002-03       Impact factor: 32.976

Review 2.  "Wish bias" in antidepressant drug trials?

Authors:  Corrado Barbui; Andrea Cipriani; Paolo Brambilla; Matthew Hotopf
Journal:  J Clin Psychopharmacol       Date:  2004-04       Impact factor: 3.153

Review 3.  Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.

Authors:  Christopher K Daugherty; Mark J Ratain; Ezekiel J Emanuel; Ann T Farrell; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.